MANGOCEUTICALS, INC. COMMON STOCK (NASDAQ: MGRX)

MANGOCEUTICALS, INC. COMMON STOCK

NASDAQ: MGRX (Mangoceuticals, Inc.)

Last update: 21 Apr, 10:56AM

2.62

0.05 (1.99%)

Add to watchlist

Previous Close	2.57
Open	2.59
Volume	128,872
Avg. Volume (3M)	174,373
Market Cap	13,547,941

Price / Sales	8.26
Price / Book	0.950

52 Weeks Range

1.49 (-43%) — 16.80 (540%)

Market Trend

		Short Term	Medium Term
Industry	Health Information Services (US)	Bearish	Mixed
	Health Information Services (Global)	Bearish	Mixed
Stock	Mangoceuticals, Inc.	-	-

AIStockmoo Score

-1.0

Analyst Consensus	-2.0
Insider Activity	1.5
Price Volatility	-2.0
Technical Moving Averages	0.0
Technical Oscillators	-2.5
Average	-1.00

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
MGRX	14 M	-	-	0.950
SY	81 M	3.23%	-	0.330
VSEE	19 M	-	-	3.95
BFRG	16 M	-	-	3.36
VSEEW	-	-	-	-
ACONW	-	-	-	-

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men’s wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
Sector	Healthcare
Industry	Health Information Services
% Held by Insiders	34.89%
% Held by Institutions	1.48%

Ownership

Name	Date	Shares Held
Ackerman Capital Advisors, Llc	31 Dec 2024	34,500
Mccollum Christoferson Group Llc	31 Dec 2024	0

No data within this time range.

Date	Type	Details
28 Apr 2025	Announcement	ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market
26 Apr 2025	Announcement	CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth O...
25 Apr 2025	Announcement	ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector
25 Apr 2025	Announcement	Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
22 Apr 2025	Announcement	CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape
25 Mar 2025	Announcement	Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada
20 Feb 2025	Announcement	Mangoceuticals Announces the Launch of “PeachesRx” - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments
12 Feb 2025	Announcement	Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution
06 Feb 2025	Announcement	Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research
03 Feb 2025	Announcement	Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Operating Margin (TTM)	-2,264.62%
Diluted EPS (TTM)	-4.84
Quarterly Revenue Growth (YOY)	-56.90%

Total Debt/Equity (MRQ)	1.54%
Current Ratio (MRQ)	0.050
Operating Cash Flow (TTM)	-4.86 M
Levered Free Cash Flow (TTM)	-1.09 M

Return on Assets (TTM)	-62.72%
Return on Equity (TTM)	-118.31%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)